A mandibular advancement device did not affect daytime sleepiness and quality of life in obstructive sleep apnoea

Context Obstructive sleep apnoea (OSA) is a sleep-related breathing disorder, characterised by (intense) snoring and recurrent obstructions of the upper airway during sleep. Among other things, OSA is associated with cardiovascular complications and increased mortality. Oral appliances that move the mandible into a more anterior position, commonly known as mandibular advancement devices (MAD), have gained popularity as an alternative to continuous positive airway pressure (CPAP) therapy. It aims at relieving upper airway obstruction by positioning the mandible and its attached soft tissue structures in a forward and downward position during sleep. In this clinical trial, Marklund and colleagues examined the objective and subjective effects of MAD therapy on daytime sleepiness and quality of life (QOL) compared with placebo therapy.